Trending...
- ResC4EU Final Event at KOMPOZYT-EXPO 2026 – Building Resilient European Supply Chains
- CinderLabs Launches AI Agent Marketplace: Nine Pre-Built Agents for Regulated Industries
- Harvard Educated Board Certified Endodontist Joins Pearlfection Dentistry
SEATTLE ~ Seattle, WA - Tasso, Inc., a leading provider of patient-centric blood collection solutions, has announced the launch of their new service, Tasso Care® for Prescreening. This end-to-end solution aims to improve the success of prescreening programs by expanding on the company's expertise in remote blood collection and analysis.
Tasso Care for Prescreening is specifically designed to support the prescreening of participants in clinical trials for various cardiometabolic and serostatus markers. The company plans to add additional panels for immunology, cardiovascular disease, and other therapeutic areas throughout the first quarter of 2024 as validation protocols are completed.
According to Tasso CEO and Co-Founder Ben Casavant, PhD, screening participants is a major bottleneck in drug development that often leads to trial delays and high screen failure rates. With Tasso Care, this process is revolutionized by replacing time-consuming clinic visits with convenient and automated prescreening testing at scale.
More on Washingtoner
By offering a virtually painless blood draw experience from the comfort of home, Tasso aims to increase clinical trial engagement rates by simplifying the operational process and optimizing the participants' experience. This also ensures a high-quality sample is returned to the lab. Additionally, Tasso Care allows for large populations to be screened simultaneously anytime and anywhere, ultimately increasing trial access and diversity.
Casavant believes that accelerating and expanding access to clinical trials is crucial in improving healthcare. He states that trials often face enrollment delays due to difficulties in identifying rare populations and obtaining up-to-date data. With Tasso Care for Prescreening, these challenges can be overcome as screening becomes more scalable and convenient.
It should be noted that Tasso Care for Prescreening is intended for use under institutional review board (IRB)-reviewed prescreening protocols. To learn more about this new service from Tasso Inc., please visit their website at www.tassoinc.com/prescreening.
Tasso Care for Prescreening is specifically designed to support the prescreening of participants in clinical trials for various cardiometabolic and serostatus markers. The company plans to add additional panels for immunology, cardiovascular disease, and other therapeutic areas throughout the first quarter of 2024 as validation protocols are completed.
According to Tasso CEO and Co-Founder Ben Casavant, PhD, screening participants is a major bottleneck in drug development that often leads to trial delays and high screen failure rates. With Tasso Care, this process is revolutionized by replacing time-consuming clinic visits with convenient and automated prescreening testing at scale.
More on Washingtoner
- NEW Three Fully Furnished Single-Family Model Homes at Heritage at South Brunswick
- After 35 Years, Christian Radio Host Marina Maria Publishes the Novel She Never Forgot
- Freight Broker 911 CEO and President Milton Collier Is Rebuilding the Path Into Freight Brokerage
- Tacoma: Homicide Investigation Update
- Boston Industrial Solutions Launches New and Improved Siliart Website for Silicone Decorators
By offering a virtually painless blood draw experience from the comfort of home, Tasso aims to increase clinical trial engagement rates by simplifying the operational process and optimizing the participants' experience. This also ensures a high-quality sample is returned to the lab. Additionally, Tasso Care allows for large populations to be screened simultaneously anytime and anywhere, ultimately increasing trial access and diversity.
Casavant believes that accelerating and expanding access to clinical trials is crucial in improving healthcare. He states that trials often face enrollment delays due to difficulties in identifying rare populations and obtaining up-to-date data. With Tasso Care for Prescreening, these challenges can be overcome as screening becomes more scalable and convenient.
It should be noted that Tasso Care for Prescreening is intended for use under institutional review board (IRB)-reviewed prescreening protocols. To learn more about this new service from Tasso Inc., please visit their website at www.tassoinc.com/prescreening.
0 Comments
Latest on Washingtoner
- Guardian Data Opens 42,000-Square-Foot Moonachie Facility, Doubling New Jersey Capacity
- Spokane: Indigenous Peoples' Day Is Oct. 12
- SecureMaine 2026 is Here -- Thursday October 8th!
- Tacoma: Homicide Investigation – 800 Pacific Avenue
- HW Foundation Opens Nominations for Inaugural 50 Under 50 in AI; Deadline Oct. 16
- Pavillon 30 Years of Addiction Recovery in Western North Carolina, Earns National Accreditation
- Safer Spokane
- Spokane: Special Investigation Unit Seized Large Amounts of Cash and Cocaine
- Spokane: U.S. Conference of Mayors, American Beverage Foundation Visit Youth Wellness Zone
- Spokane: Disabled Smoke Alarm Contributes to Fatal Tiki Lodge Fire
- Spokane Police Investigate Fatal Fire With Fire Department
- Spokane: SPD and SFD Respond to Early Morning Fire in Downtown Apartments
- City To Simplify Services by Routing Non-Emergency Police, Fire Calls through Spokane 311
- ResC4EU Final Event at KOMPOZYT-EXPO 2026 – Building Resilient European Supply Chains
- Tacoma: Update Fourth Homicide Arrest – 2100 block of N 30th St
- City of Tacoma Invites Community Members to Share Their Experience Crossing I-5
- Statement from Tacoma Chief of Police Patti Jackson on Understanding the Office of Independent Investigations (OII)
- Tacoma: 2026 AMOCAT Arts Award Winners Announced
- City of Tacoma Awarded Competitive State Grant to Evaluate Residential Development Regulations and Permit Processing Times
- City of Tacoma to Host 'Picture Pac Ave' Code Update Open House on October 20